A Prospective, Randomized Trial Comparing Hydromorphone and Nalbuphine for Postcesarean Patient-Controlled Analgesia and Developing a Risk Prediction Model for Inadequate Analgesia
Nalbuphine demonstrated superior analgesia and fewer adverse effects compared with hydromorphone for postcesarean PCA. The developed predictive model may support individualized pain management by identifying patients at risk for inadequate analgesia.
Authors
- Jiaoli Sun (ORCID: https://orcid.org/0009-0005-3099-0396)
- Wencui Zhang (ORCID: https://orcid.org/0000-0002-1315-3765)
- Shangchen Yu (ORCID: https://orcid.org/0009-0001-5942-8218)
- Zhiqiang Zhou (ORCID: https://orcid.org/0000-0003-2241-205X)
- Xueqin Cao
- Bo Jiao (ORCID: https://orcid.org/0000-0002-8173-8060)
- Guanglei Zhang (ORCID: https://orcid.org/0000-0002-2617-9673)
- Cai‐Xia Zhang (ORCID: https://orcid.org/0000-0001-9671-9412)
- Xianwei Zhang (ORCID: https://orcid.org/0000-0001-9361-8202)
- Kaiwen Zhang (ORCID: https://orcid.org/0000-0002-5267-3958)
Institutions
- Wuhan No.1 Hospital (CN)
- Wuhan No.9 Hospital (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2025-10-31
- DOI
- https://doi.org/10.2147/dddt.s551186
- Primary Topic
- Anesthesia and Pain Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Huazhong University of Science and Technology
- Natural Science Foundation of Hubei Province
- Tongji University
- National Health Commission of the People's Republic of China
- Tongji Medical College, Huazhong University of Science and Technology